查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生物製品市場評估:按產品,應用,藥物類別,採購方式,分銷管道,地區,機會和預測（2017-2031）
市場調查報告書
商品編碼
1417589

全球生物製品市場評估:按產品,應用,藥物類別,採購方式,分銷管道,地區,機會和預測（2017-2031）

Biologics Market Assessment, By Product By Application By Drug Classification, By Mode of Purchase By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

預計2023年全球生物製品市場規模將達4,013.4億美元，2031年將達6,957.9億美元，2024-2031年預測期間內複合年增長率為7.12%。慢性病的盛行率和診斷率不斷上升，對先進的診斷和治療藥物產生了巨大的需求，從而推動了全球生物製品市場的發展。這些專門的藥物經過基因改造，以針對引起發炎的免疫系統的特定成分。隨著 COVID-19 疾病的出現，世界各國政府正在採取措施加強醫療產業並確保生物製劑的供應。

同時，科學家和研究人員正在探索不同的物種和表現系統，以提高生物製劑的效率。此外，許多製藥公司正在進行旨在提高關節炎口服藥物有效性的研究和開發。由於小分子藥物研發的生產力下降，預計未來幾年生物製劑市場將出現重大飛躍。這些製藥公司正在積極開發各種生物製劑，以維持其市場主導地位。隨著治療克隆氏症和類風濕性關節炎等疾病的口服藥物變得更加有效，預計將有更多的中度疾病患者轉向新品牌的治療。此外，這些新化合物為對傳統治療有抵抗力的患者提供了替代治療，並且通常表現出卓越的安全性和有效性。

慢性病盛行率高

全球生物製品市場受到慢性病高盛行率的顯著影響。癌症、糖尿病、自體免疫疾病和心血管疾病等慢性疾病在世界各地變得越來越普遍。生物製劑，即從生物體中提取的藥物，已成為許多此類疾病的重要治療選擇。這些複雜的分子提供標靶治療，並且通常比傳統藥物更有效且副作用更少。

例如，根據世界衛生組織（WHO）2023年9月發布的報告，每年約有4100萬人死於非傳染性疾病（NCD），佔全球死亡總人數的74%。到 ％。每年，大約有 1700 萬人在 70 歲之前死於非傳染性疾病，其中 86% 的過早死亡發生在全球。全球每年有超過 4,100 萬人死於慢性病。其中，心血管疾病每年導致1790萬人死亡，其次是癌症、糖尿病和呼吸系統疾病。這四類疾病合計佔慢性病死亡人數的 80%。慢性病的流行正在推動診斷和治療的進步。

更加重視研究和開發

市場擴張是由對研發活動的日益重視所推動的，預計將為生物製品市場的成長提供良好的前景。此外，科學家和研究人員正在探索不同的物種和表現系統，以提高生物製劑的生產力。一些製藥公司從事研究和開發活動，旨在提高口服藥物治療類風濕性關節炎和克隆氏症等疾病的有效性。此外，加速藥物審批和推出也支持了市場成長軌跡。

例如，2023年1月，lecanemab透過美國FDA加速審批途徑獲準用於治療阿茲海默症。2022年6月，Alnylam 的 Amvtra 獲得 FDA 批准，這是一種 RNAi 療法，用於治療與遺傳性轉甲狀腺素蛋白介導的澱粉樣變性相關的多發性神經病變。

各大企業加大投資力度

全球生物製品市場主要參與者的投資持續激增，顯示該行業的成長和潛力。各大製藥公司、生技公司和研究機構都在生物製劑的研究、開發和製造方面投入大量資金。這些注資旨在加強創新、擴大產品組合併改善製造技術，最終滿足對先進個人化醫療解決方案不斷增長的需求。

競爭格局正在迅速演變，該公司計劃推出新的生物製劑，重點關注癌症、自體免疫疾病和傳染病等多種治療領域。不斷增長的投資趨勢表明業界對市場光明的未來充滿信心，推動突破性進展並改善治療方案以應對世界醫療挑戰。

本報告研究和分析了全球生物製品市場，提供市場規模和預測、市場動態、主要參與者趨勢和前景等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章 COVID-19對全球生物製品市場的影響

第 4 章執行摘要

第五章 全球生物製品市場展望（2017-2031）

  • 市場規模及預測
    • 金錢數額
    • 數量
  • 按產品
    • 單克隆抗體
    • 重組荷爾蒙/蛋白質
    • 疫苗接種
    • 基於細胞的生物製劑
    • 基於基因的生物製劑
    • 治療酵素
    • 其他
  • 按用途
    • 感染
    • 癌症
    • 自身免疫性疾病
    • 心血管
    • 血液病
    • 其他
  • 按藥品分類
    • 品牌藥品
    • 仿製藥
  • 按購買方式
    • 處方藥
    • 非處方藥
  • 按分銷渠道
    • 醫院藥房
    • 零售藥店
    • 網上藥店
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 市場佔有率：依公司劃分（2023 年）

第六章 全球生物製品市場展望：按地區（2017-2031）

  • 北美
    • 市場規模及預測
    • 按產品
    • 按用途
    • 按藥品分類
    • 按購買方式
    • 按分銷渠道
    • 美國
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第 7 章 市場測繪（2023）

  • 按產品
  • 按用途
  • 按藥品分類
  • 按購買方式
  • 按分銷渠道
  • 按地區

第八章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析 - 數量和價值
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第九章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第十章 監理框架與創新

  • 臨床試驗
  • 專利情況
  • 監管審批
  • 創新/新技術

第十一章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT分析（5家進入市場的公司）
  • 專利分析（如果適用）

第12章價格分析

第十三章案例研究

第十四章 主要公司展望

  • F. Hoffmann La-Roche Ltd.
  • Samsung Biologics
  • Amgen Inc.
  • Novo Nordisk A/S
  • AbbVie Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Celltrion Healthcare Co., Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

第十五章 戰略建議

第十六章 關於我們公司、免責聲明

Product Code: MX10883

Global biologics market size was valued at USD 401.34 billion in 2023, and is expected to reach USD 695.79 billion in 2031, with a CAGR of 7.12% for the forecast period between 2024 and 2031F. The increasing incidence and diagnosis of chronic diseases have created a significant demand for advanced diagnostics and treatment medications, consequently propelling the global biologics market. These specialized drugs have been genetically altered to target specific components of the immune system that trigger inflammation. With the emergence of coronavirus diseases, governments worldwide are taking measures to fortify the healthcare industry and ensure the availability of biologics.

Simultaneously, scientists and researchers are exploring different species and expression systems to enhance the efficiency of biological products. Moreover, numerous pharmaceutical companies are engaged in research and development efforts aimed at enhancing the effectiveness of oral medications for arthritis. Given the decline in productivity in small molecule medication research and development, a substantial surge in the biologics market is anticipated in the coming years. These pharmaceutical firms are actively pursuing the development of various biologic medications to sustain their market dominance. As oral medications for conditions like Crohn's disease and rheumatoid arthritis become more effective, it is predicted that a larger number of moderately affected patients will transition towards newly branded therapies. Additionally, these new compounds provide therapeutic alternatives for patients who have previously shown resistance to traditional treatments, often displaying superior safety and efficacy.

High Prevalence of Chronic Diseases

The global biologics market is witnessing a significant impact due to the high prevalence of chronic diseases. Chronic conditions like cancer, diabetes, autoimmune disorders, and cardiovascular diseases are increasingly becoming prevalent globally. Biologics, which are medicinal products derived from living organisms, have emerged as a critical treatment option for many of these conditions. These complex molecules offer targeted therapies, often with fewer side effects and greater efficacy than traditional pharmaceuticals.

For instance, as per the World Health Organization's report in September 2023, approximately 41 million individuals succumb annually to non-communicable diseases (NCD), representing 74% of the total global deaths. Each year, roughly 17 million people perish from NCDs before reaching the age of 70, with 86% of these untimely fatalities occurring on a global scale. Over 41 million individuals globally succumb to chronic diseases annually. Among these, cardiovascular disease leads, causing 17.9 million deaths per year, followed by cancer, diabetes, and respiratory disorders. Together, these four categories account for 80% of all fatalities attributed to chronic diseases. The prevalence of chronic diseases has spurred the advancement of diagnostics and treatments. Biologics, genetically engineered medications, and target specific components of the immune system are responsible for inflammation.

Increasing Emphasis on Research and Development

The expansion of the market is being driven by the increasing emphasis on research and development activities, which is expected to create advantageous prospects for biologics market growth. Moreover, scientists and researchers are exploring various species and expression systems to enhance the productivity of biological products. Several pharmaceutical companies are engaged in research and development activities aimed at improving the effectiveness of oral medications for conditions like rheumatoid arthritis and Crohn's disease. Furthermore, the escalating rate of drug approvals and introductions will continue to accelerate the growth trajectory of the market.

For instance, as an example, in January 2023, Lecanemab received approval from the U.S. FDA via its accelerated approval pathway, specifically intended for addressing Alzheimer's Disease. In June 2022, Alnylam Pharmaceuticals, Inc. obtained FDA approval for its RNAi therapeutic, AMVUTTRA, designed for treating the Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

Growing Investments by Key Players

The global biologics market continues to witness a surge in investments by key players, indicative of the sector's growth and potential. Major pharmaceutical companies, biotech firms, and research institutions are channeling substantial investments into research, development, and manufacturing of biologics. The financial commitment aims to bolster innovation, expand product portfolios, and enhance manufacturing technologies, ultimately meeting the rising demand for advanced and personalized healthcare solutions.

The competitive landscape is evolving rapidly as companies are planning to introduce novel biologics, focusing on diverse therapeutic areas like oncology, autoimmune diseases, and infectious diseases. The growing investment trend signifies the industry's confidence in the market's promising future, fostering groundbreaking advancements and improved treatment options for global healthcare challenges. For Instance, in March 2023, Novartis announced the intention of its division, Sandoz to allocate roughly USD 400 million towards establishing a biologics manufacturing plant situated in Slovenia. During March 2023, Eli Lilly disclosed its proposal to invest USD 500 million into expanding its current 500,000 sq. ft. biologics manufacturing site in Limerick.

Technological Advancements

The global biologics market has witnessed remarkable technological advancements, revolutionizing the landscape of medicine and healthcare. Innovations in biotechnology, particularly in areas like genetic engineering, monoclonal antibodies, and recombinant DNA technology, have significantly enhanced the development and production of biologics industry.

Advanced techniques in cell culture systems, gene editing (like CRISPR), and bioprocessing have streamlined the manufacturing of complex biological molecules. Furthermore, the emergence of personalized medicine has driven a shift towards more tailored and effective treatments, utilizing biologics designed to target specific patient populations. The progress has led to the development of novel biologics, including therapeutic proteins, vaccines, and monoclonal antibodies, fostering breakthroughs in treating various diseases like cancer, autoimmune disorders, and infectious diseases.

For Instance, in February 2022 CARVYKTI, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson obtained approval from the US Food and Drug Administration (FDA) for sale. The biologic medication is designated for individuals with relapsed or refractory multiple myeloma (RRMM) who have undergone four prior lines of therapy, which may include proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody treatments.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global biologics market. Biologics are complex, large-molecule drugs used to treat a variety of diseases, including autoimmune disorders, cancer, and infectious diseases. The pandemic disrupted supply chains and manufacturing processes, leading to production delays and shortages of some biologics. Additionally, the increased focus on vaccine development and monoclonal antibody therapies to combat the virus diverted resources and attention from other biologic drug development efforts.

On the contrary, the pandemic has highlighted the importance of biotechnology and accelerated innovation in the field. The rapid development of mRNA vaccines, such as the Pfizer-BioNTech and Moderna vaccines, showcased the potential of biologics in responding to infectious diseases. Furthermore, the pandemic has driven investment in research and development of biologics, leading to advancements in bioprocessing and manufacturing technologies. During April 2022, GSK, a British multinational pharmaceutical and biotechnology company, together with SK bioscience, presented a biologics license application for SKYCovione, a COVID-19 vaccine candidate based on recombinant proteins, to the Korean Ministry of Food and Drug Safety (KMFDS).

Key Players Landscape and Outlook

Prominent industry stakeholders are allocating significant funds to research and development endeavors, aiming to diversify their product portfolios, thereby stimulating the expansion of the global biologics market. The market participants are implementing various strategic measures to enhance their global presence, including pivotal actions such as launching new products, engaging in mergers and acquisitions, forming contractual agreements, amplifying investments, and fostering collaborations with other organizations. In the competitive landscape of the biologics sector, companies must provide cost-effective offerings to broaden their scope and endure in an intensifying, competitive, and burgeoning market environment.

For Instance, the FDA granted approval to Leqembi (lecanemab-irmb) through the Accelerated Approval pathway in January 2023 for addressing Alzheimer's disease. The medication diminishes amyloid-B plaques and moderately retards mild cognitive decline in individuals with early-stage Alzheimer's disease.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Biologics Market

4. Executive Summary

5. Global Biologics Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Product
    • 5.2.1. Monoclonal Antibodies
    • 5.2.2. Recombinant Hormones/Proteins
    • 5.2.3. Vaccines
    • 5.2.4. Cellular Based Biologics
    • 5.2.5. Gene-Based Biologics
    • 5.2.6. Therapeutic Enzymes
    • 5.2.7. Others
  • 5.3. By Application
    • 5.3.1. Infectious Diseases
    • 5.3.2. Cancer
    • 5.3.3. Autoimmune Diseases
    • 5.3.4. Cardiovascular
    • 5.3.5. Hematological Disorders
    • 5.3.6. Others
  • 5.4. By Drug Classification
    • 5.4.1. Branded Drugs
    • 5.4.2. Generic Drugs
  • 5.5. By Mode of Purchase
    • 5.5.1. Prescription Drugs
    • 5.5.2. Over-the-counter Drugs
  • 5.6. By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Retail Pharmacies
    • 5.6.3. Online Pharmacies
    • 5.6.4. Others
  • 5.7. By Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. South America
    • 5.7.5. Middle East & Africa
  • 5.8. By Company Market Share (%), 2023

6. Global Biologics Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Product
      • 6.1.2.1. Monoclonal Antibodies
      • 6.1.2.2. Recombinant Hormones/Proteins
      • 6.1.2.3. Vaccines
      • 6.1.2.4. Cellular Based Biologics
      • 6.1.2.5. Gene-Based Biologics
      • 6.1.2.6. Therapeutic Enzymes
      • 6.1.2.7. Others
    • 6.1.3. By Application
      • 6.1.3.1. Infectious Diseases
      • 6.1.3.2. Cancer
      • 6.1.3.3. Autoimmune Diseases
      • 6.1.3.4. Cardiovascular
      • 6.1.3.5. Hematological Disorders
      • 6.1.3.6. Others
    • 6.1.4. By Drug Classification
      • 6.1.4.1. Branded Drugs
      • 6.1.4.2. Generic Drugs
    • 6.1.5. By Mode of Purchase
      • 6.1.5.1. Prescription Drugs
      • 6.1.5.2. Over-the-counter Drugs
    • 6.1.6. By Distribution Channel
      • 6.1.6.1. Hospital Pharmacies
      • 6.1.6.2. Retail Pharmacies
      • 6.1.6.3. Online Pharmacies
      • 6.1.6.4. Others
    • 6.1.7. United States*
      • 6.1.7.1. By Product
      • 6.1.7.1.1. Monoclonal Antibodies
      • 6.1.7.1.2. Recombinant Hormones/Proteins
      • 6.1.7.1.3. Vaccines
      • 6.1.7.1.4. Cellular Based Biologics
      • 6.1.7.1.5. Gene-Based Biologics
      • 6.1.7.1.6. Therapeutic Enzymes
      • 6.1.7.1.7. Others
      • 6.1.7.2. By Application
      • 6.1.7.2.1. Infectious Diseases
      • 6.1.7.2.2. Cancer
      • 6.1.7.2.3. Autoimmune Diseases
      • 6.1.7.2.4. Cardiovascular
      • 6.1.7.2.5. Hematological Disorders
      • 6.1.7.2.6. Others
      • 6.1.7.3. By Drug Classification
      • 6.1.7.3.1. Branded Drugs
      • 6.1.7.3.2. Generic Drugs
      • 6.1.7.4. By Mode of Purchase
      • 6.1.7.4.1. Prescription Drugs
      • 6.1.7.4.2. Over-the-counter Drugs
      • 6.1.7.5. By Distribution Channel
      • 6.1.7.5.1. Hospital Pharmacies
      • 6.1.7.5.2. Retail Pharmacies
      • 6.1.7.5.3. Online Pharmacies
      • 6.1.7.5.4. Others
      • 6.1.7.6. By Region
      • 6.1.7.6.1. North America
      • 6.1.7.6.2. Europe
      • 6.1.7.6.3. Asia Pacific
      • 6.1.7.6.4. South America
      • 6.1.7.6.5. Middle East & Africa
      • 6.1.7.7. Canada
      • 6.1.7.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Product
  • 7.2. By Application
  • 7.3. By Drug Classification
  • 7.4. By Mode of Purchase
  • 7.5. By Distribution Channel
  • 7.6. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. F. Hoffmann La-Roche Ltd.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Samsung Biologics
  • 14.3. Amgen Inc.
  • 14.4. Novo Nordisk A/S
  • 14.5. AbbVie Inc.
  • 14.6. Sanofi
  • 14.7. Johnson & Johnson Services, Inc.
  • 14.8. Celltrion Healthcare Co., Ltd.
  • 14.9. Bristol-Myers Squibb Company
  • 14.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Biologics Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Biologics Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 6. Global Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 7. Global Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Global Biologics Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 11. North America Biologics Market Share (%), By Product, 2017-2031F
  • Figure 12. North America Biologics Market Share (%), By Application, 2017-2031F
  • Figure 13. North America Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 14. North America Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 15. North America Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 16. North America Biologics Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 19. United States Biologics Market Share (%), By Product, 2017-2031F
  • Figure 20. United States Biologics Market Share (%), By Application, 2017-2031F
  • Figure 21. United States Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 22. United States Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 23. United States Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 24. Canada Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 26. Canada Biologics Market Share (%), By Product, 2017-2031F
  • Figure 27. Canada Biologics Market Share (%), By Application, 2017-2031F
  • Figure 28. Canada Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 29. Canada Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 30. Canada Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. Mexico Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 33. Mexico Biologics Market Share (%), By Product, 2017-2031F
  • Figure 34. Mexico Biologics Market Share (%), By Application, 2017-2031F
  • Figure 35. Mexico Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 36. Mexico Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 37. Mexico Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 38. Europe Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 40. Europe Biologics Market Share (%), By Product, 2017-2031F
  • Figure 41. Europe Biologics Market Share (%), By Application, 2017-2031F
  • Figure 42. Europe Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 43. Europe Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 44. Europe Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 45. Europe Biologics Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. Germany Biologics Market Share (%), By Product, 2017-2031F
  • Figure 49. Germany Biologics Market Share (%), By Application, 2017-2031F
  • Figure 50. Germany Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 51. Germany Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 52. Germany Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 53. France Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 55. France Biologics Market Share (%), By Product, 2017-2031F
  • Figure 56. France Biologics Market Share (%), By Application, 2017-2031F
  • Figure 57. France Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 58. France Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 59. France Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60. Italy Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 62. Italy Biologics Market Share (%), By Product, 2017-2031F
  • Figure 63. Italy Biologics Market Share (%), By Application, 2017-2031F
  • Figure 64. Italy Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 65. Italy Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 66. Italy Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67. United Kingdom Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 69. United Kingdom Biologics Market Share (%), By Product, 2017-2031F
  • Figure 70. United Kingdom Biologics Market Share (%), By Application, 2017-2031F
  • Figure 71. United Kingdom Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 72. United Kingdom Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 73. United Kingdom Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Russia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 76. Russia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 77. Russia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 78. Russia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 79. Russia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 80. Russia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Netherlands Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 83. Netherlands Biologics Market Share (%), By Product, 2017-2031F
  • Figure 84. Netherlands Biologics Market Share (%), By Application, 2017-2031F
  • Figure 85. Netherlands Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 86. Netherlands Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 87. Netherlands Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Spain Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Spain Biologics Market Share (%), By Product, 2017-2031F
  • Figure 91. Spain Biologics Market Share (%), By Application, 2017-2031F
  • Figure 92. Spain Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 93. Spain Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 94. Spain Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Turkey Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 97. Turkey Biologics Market Share (%), By Product, 2017-2031F
  • Figure 98. Turkey Biologics Market Share (%), By Application, 2017-2031F
  • Figure 99. Turkey Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 100. Turkey Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 101. Turkey Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102. Poland Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 104. Poland Biologics Market Share (%), By Product, 2017-2031F
  • Figure 105. Poland Biologics Market Share (%), By Application, 2017-2031F
  • Figure 106. Poland Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 107. Poland Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 108. Poland Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 109. South America Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 111. South America Biologics Market Share (%), By Product, 2017-2031F
  • Figure 112. South America Biologics Market Share (%), By Application, 2017-2031F
  • Figure 113. South America Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 114. South America Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 115. South America Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. South America Biologics Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 119. Brazil Biologics Market Share (%), By Product, 2017-2031F
  • Figure 120. Brazil Biologics Market Share (%), By Application, 2017-2031F
  • Figure 121. Brazil Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 122. Brazil Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 123. Brazil Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124. Argentina Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 126. Argentina Biologics Market Share (%), By Product, 2017-2031F
  • Figure 127. Argentina Biologics Market Share (%), By Application, 2017-2031F
  • Figure 128. Argentina Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 129. Argentina Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 130. Argentina Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Asia-Pacific Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 133. Asia-Pacific Biologics Market Share (%), By Product, 2017-2031F
  • Figure 134. Asia-Pacific Biologics Market Share (%), By Application, 2017-2031F
  • Figure 135. Asia-Pacific Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 136. Asia-Pacific Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 137. Asia- Pacific Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Asia-Pacific Biologics Market Share (%), By Country, 2017-2031F
  • Figure 139. India Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 141. India Biologics Market Share (%), By Product, 2017-2031F
  • Figure 142. India Biologics Market Share (%), By Application, 2017-2031F
  • Figure 143. India Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 144. India Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 145. India Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. China Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 148. China Biologics Market Share (%), By Product, 2017-2031F
  • Figure 149. China Biologics Market Share (%), By Application, 2017-2031F
  • Figure 150. China Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 151. China Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 152. China Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 153. Japan Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 155. Japan Biologics Market Share (%), By Product, 2017-2031F
  • Figure 156. Japan Biologics Market Share (%), By Application, 2017-2031F
  • Figure 157. Japan Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 158. Japan Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 159. Japan Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 160. Australia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 162. Australia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 163. Australia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 164. Australia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 165. Australia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 166. Australia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 167. Vietnam Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 169. Vietnam Biologics Market Share (%), By Product, 2017-2031F
  • Figure 170. Vietnam Biologics Market Share (%), By Application, 2017-2031F
  • Figure 171. Vietnam Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 172. Vietnam Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 173. Vietnam Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. South Korea Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 176. South Korea Biologics Market Share (%), By Product, 2017-2031F
  • Figure 177. South Korea Biologics Market Share (%), By Application, 2017-2031F
  • Figure 178. South Korea Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 179. South Korea Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 180. South Korea Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. Indonesia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. Indonesia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 184. Indonesia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 185. Indonesia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 186. Indonesia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 187. Indonesia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 188. Philippines Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 190. Philippines Biologics Market Share (%), By Product, 2017-2031F
  • Figure 191. Philippines Biologics Market Share (%), By Application, 2017-2031F
  • Figure 192. Philippines Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 193. Philippines Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 194. Philippines Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 195. Middle East & Africa Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 197. Middle East & Africa Biologics Market Share (%), By Product, 2017-2031F
  • Figure 198. Middle East & Africa Biologics Market Share (%), By Application, 2017-2031F
  • Figure 199. Middle East & Africa Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 200. Middle East & Africa Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 201. Middle East & Africa Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 202. Middle East & Africa Biologics Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 205. Saudi Arabia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 206. Saudi Arabia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 207. Saudi Arabia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 208. Saudi Arabia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 209. Saudi Arabia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 210. UAE Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 212. UAE Biologics Market Share (%), By Product, 2017-2031F
  • Figure 213. UAE Biologics Market Share (%), By Application, 2017-2031F
  • Figure 214. UAE Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 215. UAE Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 216. UAE Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 217. South Africa Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 219. South Africa Biologics Market Share (%), By Product, 2017-2031F
  • Figure 220. South Africa Biologics Market Share (%), By Application, 2017-2031F
  • Figure 221. South Africa Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 222. South Africa Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 223. South Africa Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 224. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Drug Classification Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Mode of Purchase Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023